RTI introduces next generation of BioCleanse, restructures agreement with MSD.
The BioCleanse system is a low temperature chemical sterilization process that eliminates bacteria, fungi and spores, as well as enveloped and non-enveloped viruses such as HIV and hepatitis from tissue, without altering the strength or biocompatibility of the allograft, RTI says. Earlier this year the FDA completed a compliance review of the process and determined that RTI had successfully validated the process. (Transplant News, February 27, 2002)
RTI also announced it has agreed to new terms with Medtronic Sofamor Danek (MSD) for an exclusive license and distribution agreement to supply human allograft tissue and bone paste for spine surgery.
MSD will continue to serve as exclusive worldwide distributor for specialty tissue allografts and bone paste processed by RTI for use in spinal surgery. Under the new agreement, the companies have agreed to co-develop new tissue-based spine surgery solutions and restructure financial terms to reflect the value of RTI's proprietary technology including its BioCleanse process.
Contact: Quenta Vettel - (386) 318-8888
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Medtronic Sofamor Danek|
|Comment:||RTI introduces next generation of BioCleanse, restructures agreement with MSD.(Medtronic Sofamor Danek)|
|Article Type:||Brief Article|
|Date:||Jul 12, 2002|
|Previous Article:||CryoLife admits misstatements contained in press release about FDA warning letter.|
|Next Article:||LifeCell, LifeNet and Arthrex team up to deliver acceluar allografts for sports medicine.|